[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"osteonecrosis-of-the-femoral-head\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:osteonecrosis-of-the-femoral-head":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100634894","screening-for-biomarkers-of-osteonecrosis-of-the-femoral-head-100634894",false,"NCT07545616","Screening for Biomarkers of Osteonecrosis of the Femoral Head","Screening of Biomarkers for Osteonecrosis of the Femoral Head and Establishment of a Multidimensional Data Based Early Diagnostic Method","Inclusion Criteria:\n\n1. Aged between 18 and 70 years old (inclusive).\n2. Patients with suspected ONFH.\n3. Those who provide informed consent and volunteer to participate in this study.\n\nExclusion Criteria:\n\n1. Patients with a clear history of hip trauma.\n2. Patients with ONFH secondary to traumatic factors such as femoral neck fracture and hip dislocation.\n3. Patients complicated with severe mental illness or cognitive impairment who are unable to cooperate with questionnaire completion.\n4. Patients who refuse to sign the informed consent form.","ALL","18 Years","70 Years",{"count":20,"type":21},300,"ESTIMATED","OBSERVATIONAL","Osteonecrosis of the femoral head (ONFH) presents a rapidly progressive natural disease course. Femoral head collapse may occur within two years, ultimately necessitating total hip arthroplasty and imposing a heavy medical and economic burden on patients. Early intervention can significantly improve the long-term prognosis of ONFH. However, due to the lack of validated biomarkers for early diagnosis, the early diagnostic rate remains low, with a primary diagnostic rate of merely 68.43% at the first visit, accompanied by a high rate of misdiagnosis. This project intends to collect blood samples from patients diagnosed with ONFH and suspected cases in the orthopedic outpatient department of a tertiary Grade A hospital. Diagnostic and differential diagnostic tests will be adopted to evaluate the clinical application value of previously reported candidate biomarkers, so as to screen out biomarkers with excellent diagnostic validity and reliability. Meanwhile, clinical data will be collected to identify independent risk factors, and a multi-dimensional integrated diagnostic model will be further established. The research findings are expected to provide solid data support, theoretical basis and technical reserves for the early prevention, early diagnosis and individualized intervention of osteonecrosis of the femoral head.",[25],"Osteonecrosis of the Femoral Head",[25,27],"Biomarker","RECRUITING","2026-04-15",{"date":31,"type":32},"2026-04-22","ACTUAL",{"date":34,"type":21},"2026-04-20",{"date":36,"type":21},"2027-05-30",{"name":38,"class":39},"The First Affiliated Hospital of Xinxiang Medical College","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":85},"100525572","autologous-bone-marrow-aspirate-treatment-for-early-stage-osteonecrosis-100525572","NCT06123481","Autologous Bone Marrow Aspirate Treatment for Early-Stage Osteonecrosis","Autologous Bone Marrow Aspirate Concentrate for the Treatment of Osteonecrosis of the Femoral Head","BATON","Inclusion Criteria\n\n* Participants who have non-traumatic osteonecrosis of the femoral head\n* Only participants who have Stage 1 or 2 osteonecrosis as assessed by the 2019 ARCO Staging System\n* No evidence of subchondral fracture\n* All osteonecrotic lesion sizes\n* All major risk factors (e.g. corticosteroids, alcohol, organ recipient) except for those listed in the exclusion criteria\n* Participants diagnosed who have femoral head osteonecrosis for which no risk factor has yet to be identified\n* Participants will include all ethnicities and races\n* Be able and willing to participate in study and return for postoperative visits\n\nExclusion Criteria\n\n* Participants who have:\n\n  * Sickle Cell disease\n  * Major trauma\n  * Post-irradiation ON\n  * Gaucher Disease\n  * Juvenile form: Legg-Calve-Perthes Disease\n  * Juvenile form: Spontaneous ON of the hip\n  * Pregnant or breastfeeding\n  * Vulnerable population; i.e., prisoners and institutionalized individuals\n* Participant is unable to undergo an MRI\n* Participants who have evidence of a subchondral fracture\n* Prior history of hip surgery, more extensive than hip arthroscopy","90 Years",{"count":51,"type":21},192,"INTERVENTIONAL",[54],"NA","Osteonecrosis of the femoral head (ONFH) is a debilitating musculoskeletal disease that is characterized by localized death of bone cells and associated cellular elements within the subchondral bone. If it progresses, it results in the collapse of the femoral head (ball part of the hip) giving rise to secondary arthritis. This condition is associated with marked pain and loss of function, often necessitating a joint replacement. Due to the relatively young age of onset of ONFH (often in 20s and 30s), there is great interest in utilizing joint-preserving procedures prior to the need for joint replacement. Joint-preserving procedures include core decompression (CD) with and without bone grafts or cells, vascularized and non-vascularized bone grafting, as well as osteotomies. Inconsistent results for each of these procedures have been reported and there are no Clinical Practice Guidelines or medical community consensus opinions regarding the treatment of early-stage ONFH. The hypothesis to be tested is \"Participants who have early-stage ONFH undergoing CD augmented with autogenous bone marrow aspirate concentrate will have better clinical and radiological outcomes than CD alone.\" This multi-center randomized controlled trial for early-stage ONFH is prospective and controlled for participant stage (only early-stage pre-collapse individuals) and surgical technique. Participants will be evaluated as per routine surgical follow-up, and at 6 months (telemedicine), 1- and 2- years using radiographs, MRIs, and questionnaires. This project will also explore the scientific basis for success vs. failure in individuals who have osteonecrosis, and have different demographics and bone marrow aspirate cell profiles.",[25,57],"Avascular Necrosis of the Femoral Head",[59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75],"osteonecrosis","aseptic necrosis","avascular necrosis (AVN)","bone marrow aspirate","bone marrow aspirate concentrate","bone marrow cells","bone marrow","cell-based treatment","core decompression","femoral head","necrosis","bone diseases","musculoskeletal diseases","pathologic processes","hip","ONFH","AVN","2025-11-25",{"date":78,"type":32},"2025-11-26",{"date":80,"type":32},"2025-04-01",{"date":82,"type":21},"2029-07-31",{"name":84,"class":39},"Johns Hopkins University",10]